[go: up one dir, main page]

MX2018014377A - Metodos para tratar infecciones por virus de hepatitis b usando inhibidores de proteina no estructural 5a (ns5a), proteina no estructural 5b (ns5b) o proteina no estructural 3 (ns3). - Google Patents

Metodos para tratar infecciones por virus de hepatitis b usando inhibidores de proteina no estructural 5a (ns5a), proteina no estructural 5b (ns5b) o proteina no estructural 3 (ns3).

Info

Publication number
MX2018014377A
MX2018014377A MX2018014377A MX2018014377A MX2018014377A MX 2018014377 A MX2018014377 A MX 2018014377A MX 2018014377 A MX2018014377 A MX 2018014377A MX 2018014377 A MX2018014377 A MX 2018014377A MX 2018014377 A MX2018014377 A MX 2018014377A
Authority
MX
Mexico
Prior art keywords
ns5b
methods
ns5a
inhibitors
virus infections
Prior art date
Application number
MX2018014377A
Other languages
English (en)
Inventor
Gaggar Anuj
Mani Subramanian G
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of MX2018014377A publication Critical patent/MX2018014377A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con métodos para tratar las infecciones por el virus de la hepatitis B mediante la administración de un inhibidor de NS5A, un inhibidor de NS5B, un inhibidor de NS3 o combinaciones de los mismos.
MX2018014377A 2016-05-27 2017-05-11 Metodos para tratar infecciones por virus de hepatitis b usando inhibidores de proteina no estructural 5a (ns5a), proteina no estructural 5b (ns5b) o proteina no estructural 3 (ns3). MX2018014377A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662342787P 2016-05-27 2016-05-27
PCT/US2017/032282 WO2017205078A1 (en) 2016-05-27 2017-05-11 Methods for treating hepatitis b virus infections using ns5a, ns5b or ns3 inhibitors

Publications (1)

Publication Number Publication Date
MX2018014377A true MX2018014377A (es) 2019-03-14

Family

ID=58745467

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018014377A MX2018014377A (es) 2016-05-27 2017-05-11 Metodos para tratar infecciones por virus de hepatitis b usando inhibidores de proteina no estructural 5a (ns5a), proteina no estructural 5b (ns5b) o proteina no estructural 3 (ns3).

Country Status (15)

Country Link
US (1) US11738013B2 (es)
EP (1) EP3463469B1 (es)
JP (2) JP6770098B2 (es)
KR (1) KR102202984B1 (es)
CN (3) CN118178652A (es)
AU (1) AU2017271990B2 (es)
BR (1) BR112018073858A2 (es)
CA (1) CA3025633C (es)
EA (1) EA201892375A1 (es)
ES (1) ES2969239T3 (es)
MA (1) MA45088A (es)
MX (1) MX2018014377A (es)
PL (1) PL3463469T3 (es)
SG (1) SG11201809893WA (es)
WO (1) WO2017205078A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7381190B2 (ja) 2014-12-26 2023-11-15 エモリー・ユニバーシテイ Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途
SG11202002431SA (en) * 2017-09-21 2020-04-29 Riboscience Llc 4'-fluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
KR102626210B1 (ko) 2017-12-07 2024-01-18 에모리 유니버시티 N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도
JP7441174B2 (ja) 2018-11-16 2024-02-29 公益財団法人東京都医学総合研究所 Ｂ型肝炎ウイルスの複製阻害組成物
EP4286044A4 (en) * 2021-02-01 2024-11-20 SM Lab Co., Ltd. CRUCIBLE AND CRUCIBLE ASSEMBLY FOR THE PREPARATION OF A CATHODE ACTIVE MATERIAL

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3521297T3 (pl) 2003-05-30 2022-04-04 Gilead Pharmasset Llc Zmodyfikowane fluorowane analogi nukleozydów
MX2007000584A (es) 2004-07-16 2007-06-25 Gilead Sciences Inc Compuestos antivirales.
TWI389908B (zh) 2005-07-14 2013-03-21 Gilead Sciences Inc 抗病毒化合物類
TWI382019B (zh) 2005-08-19 2013-01-11 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之胺基二氮雜呯
TW201402124A (zh) 2005-08-19 2014-01-16 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯
MY150667A (en) 2005-12-09 2014-02-28 Gilead Pharmasset Llc Antiviral nucleosides
ATE554776T1 (de) 2006-07-07 2012-05-15 Gilead Sciences Inc Antivirale phosphinatverbindungen
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
MX2009013832A (es) 2007-06-29 2010-03-10 Gilead Sciences Inc Derivados de purina y su uso como moduladores del receptor 7 similar a un puente.
MX2009013827A (es) 2007-06-29 2010-03-01 Gilead Sciences Inc Compuestos antivirales.
US8513186B2 (en) 2007-06-29 2013-08-20 Gilead Sciences, Inc. Antiviral compounds
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
RS57132B1 (sr) 2008-07-08 2018-07-31 Incyte Holdings Corp 1,2,5-oksadiazoli kao inhibitori indolamin 2,3-dioksigenaze
CA2732437C (en) 2008-08-01 2017-11-21 Ventirx Pharmaceuticals, Inc. Toll-like receptor agonist formulations and their use
CA2745295C (en) 2008-12-09 2017-01-10 Gilead Sciences, Inc. Modulators of toll-like receptors
CL2009002208A1 (es) 2008-12-23 2010-10-29 Gilead Pharmasset Llc Un compuesto (2s)-2-((((2r,3r,4r,5r)-5-(2-amino-6-etoxi-9h-purin-9-il)-4-fluoro-3-hidroxi-4-metiltetrahidrofuran-2-il)metoxi)(hidroxi)fosforilamino)propanoico, inhibidores de la replicacion de arn viral; composicion farmaceutica; y su uso en el tratamiento de infeccion por hepatitis c, virus del nilo occidental, entre otras.
CL2009002207A1 (es) 2008-12-23 2011-02-18 Gilead Pharmasset Llc Compuestos derivados de 3-hidroxi-5-(9h-purin-9-il)tetrahidrofuran-2-il, inhibidor de la replicacion de arn viral dependiente de arn; composicion farmaceutica; uso para el tratamiento de hepatitis c.
BRPI1010795B1 (pt) 2009-05-13 2018-12-11 Gilead Pharmasset Llc compostos antivirais, seu uso e composição farmacêutica compreendendo os mesmos
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
HUE032626T2 (en) 2009-08-18 2017-10-30 Ventirx Pharmaceuticals Inc Toll receptor modulator substituted benzoazepines
EP2467380B1 (en) 2009-08-18 2016-11-30 Ventirx Pharmaceuticals, Inc. Substituted benzoazepines as toll-like receptor modulators
SG10201406813RA (en) 2009-10-22 2014-11-27 Gilead Sciences Inc Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections
WO2011106106A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
MX2012011171A (es) 2010-03-31 2013-02-01 Gilead Pharmasset Llc Fosforamidatos de nucleosido.
TWI500617B (zh) 2010-05-31 2015-09-21 Ono Pharmaceutical Co Purine ketone derivatives
JP5951615B2 (ja) 2010-10-01 2016-07-13 ベンティアールエックス ファーマシューティカルズ， インコーポレイテッドＶｅｎｔｉＲｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Ｔｌｒアゴニストの治療用途および組み合わせ治療
US20120082658A1 (en) 2010-10-01 2012-04-05 Ventirx Pharmaceuticals, Inc. Methods for the Treatment of Allergic Diseases
SG10201509456SA (en) 2010-11-17 2015-12-30 Gilead Pharmasset Llc Antiviral compounds
AU2011336632B2 (en) 2010-11-30 2015-09-03 Gilead Pharmasset Llc Compounds
UY33775A (es) 2010-12-10 2012-07-31 Gilead Sciences Inc Inhibidores macrocíclicos de virus flaviviridae, composiciones farmacéuticas que los comprenden y sus usos
PT2663555T (pt) 2011-01-12 2017-03-23 Array Biopharma Inc Benzoazepinas substituídas como moduladores de recetores tipo-toll
DK2663550T3 (en) 2011-01-12 2017-03-27 Ventirx Pharmaceuticals Inc SUBSTITUTED BENZOAZEPINS AS MODULATORS OF TOLL-LIKE RECEPTORS
PH12013502033A1 (en) 2011-04-08 2014-01-06 Janssen Sciences Ireland Uc Pyrimidine derivatives for the treatment of viral infections
US8916575B2 (en) 2011-05-18 2014-12-23 Janssen R&D Ireland Quinazoline derivatives for the treatment of viral infections and further diseases
SMT201800470T1 (it) 2011-11-16 2018-11-09 Gilead Pharmasset Llc Imidazolilimidazoli condensati come composti antivirali
HUE031094T2 (en) 2011-11-29 2017-07-28 Ono Pharmaceutical Co Purinone derivative hydrochloride
CN106957282B (zh) 2011-12-21 2019-08-30 诺维拉治疗公司 B型肝炎抗病毒剂
DK2812331T3 (en) 2012-02-08 2019-04-08 Janssen Sciences Ireland Unlimited Co PIPERIDINOPYRIMIDINE DERIVATIVES FOR TREATING VIRUS INFECTIONS
US20130267517A1 (en) 2012-03-31 2013-10-10 Hoffmann-La Roche Inc. Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
CA2865259A1 (en) 2012-03-31 2013-10-03 F. Hoffmann-La Roche Ag Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
US20130309196A1 (en) 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds
CA2875718A1 (en) 2012-06-08 2013-12-12 Selcia Limited Macrocyclic inhibitors of flaviviridae viruses
AR091279A1 (es) 2012-06-08 2015-01-21 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae
JP6209601B2 (ja) 2012-06-08 2017-10-04 ギリアード サイエンシーズ， インコーポレイテッド フラビウイルス科ウイルスの大環状阻害剤
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
US20140019288A1 (en) 2012-07-13 2014-01-16 Overall Parts Solutions, Inc. Supply Chain Management System and Method
MX369417B (es) 2012-08-10 2019-11-07 Janssen Sciences Ireland Uc Derivados de alquilpirimidina para el tratamiento de infecciones víricas y otras enfermedades.
UA115069C2 (uk) 2012-08-28 2017-09-11 ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі Конденсовані біциклічні похідні сульфамоїлу та їх застосування як лікарських препаратів для лікування гепатиту b
AR092270A1 (es) 2012-08-28 2015-04-08 Janssen R&D Ireland Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
EP2892893B2 (en) 2012-09-10 2019-10-16 F.Hoffmann-La Roche Ag 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
PE20150998A1 (es) 2012-10-02 2015-06-29 Epitherapeutics Aps Inhibidores de histona demetilasas
US9499549B2 (en) 2012-10-10 2016-11-22 Janssen Sciences Ireland Uc Pyrrolo[3,2-]pyrimidine derivatives for the treatment of viral infections and other diseases
UA118341C2 (uk) 2012-11-16 2019-01-10 ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі Гетероциклічні заміщені похідні 2-амінохіназоліну для лікування вірусних інфекцій
MX2015007205A (es) 2012-12-06 2016-03-31 Quanticel Pharmaceuticals Inc Inhibidores de la desmetilasa de histona.
US9617242B2 (en) 2012-12-19 2017-04-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
US9233974B2 (en) 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
EA028774B1 (ru) 2012-12-21 2017-12-29 Квонтисел Фармасьютикалс, Инк. Ингибиторы гистондеметилазы
SG11201506021XA (en) * 2013-01-31 2015-08-28 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
UA118751C2 (uk) 2013-02-21 2019-03-11 ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі Похідні 2-амінопіримідину для лікування вірусних інфекцій
PL2961736T3 (pl) 2013-02-27 2018-08-31 Gilead Sciences, Inc. Inhibitory demetylaz histonowych
ES2628953T3 (es) 2013-02-28 2017-08-04 Janssen Sciences Ireland Uc Sulfamoilarilamidas y el uso de las mismas como medicamentos para el tratamiento de la hepatitis B
US20140249101A1 (en) * 2013-03-04 2014-09-04 Gilead Pharmasset Llc Methods for treating hepatitis c virus infection
US9738637B2 (en) 2013-03-12 2017-08-22 Celgene Quantical Research, Inc. Histone demethylase inhibitors
WO2014165128A2 (en) 2013-03-12 2014-10-09 Novira Therapeutics, Inc. Hepatitis b antiviral agents
US10035801B2 (en) 2013-03-13 2018-07-31 Genentech, Inc. Pyrazolo compounds and uses thereof
CA2903081A1 (en) 2013-03-14 2014-09-25 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
HRP20171609T1 (hr) 2013-03-15 2017-12-15 Quanticel Pharmaceuticals Inc Inhibitori histon demetilaze
MX353412B (es) 2013-04-03 2018-01-10 Janssen Sciences Ireland Uc Derivados de n-fenil-carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
MX2015015692A (es) 2013-05-17 2016-03-04 Hoffmann La Roche Novedosas heteroarildihidropirimidinas, unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de hepatitis b.
JP6441315B2 (ja) 2013-05-17 2018-12-19 ヤンセン・サイエンシズ・アイルランド・ユーシー スルファモイルチオフェンアミド誘導体およびｂ型肝炎を治療するための医薬品としてのその使用
PL3024819T3 (pl) 2013-07-25 2018-08-31 Janssen Sciences Ireland Uc Pochodne piroloamidowe podstawione glioksamidem i ich zastosowanie jako leków do leczenia wirusowego zapalenia wątroby typu B
SG11201602748XA (en) 2013-10-23 2016-05-30 Janssen Sciences Ireland Uc Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
US9115113B2 (en) 2013-11-14 2015-08-25 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9181288B2 (en) 2014-01-16 2015-11-10 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
WO2015113990A1 (en) 2014-01-30 2015-08-06 F. Hoffmann-La Roche Ag Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
ES2705401T3 (es) 2014-02-06 2019-03-25 Janssen Sciences Ireland Uc Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la Hepatitis B
US9400280B2 (en) 2014-03-27 2016-07-26 Novira Therapeutics, Inc. Piperidine derivatives and methods of treating hepatitis B infections
CA2948080A1 (en) 2014-05-13 2015-11-19 F. Hoffmann-La Roche Ag Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
KR101891933B1 (ko) 2014-08-14 2018-08-24 에프. 호프만-라 로슈 아게 B형 간염 바이러스 감염의 치료 또는 예방을 위한 신규한 피리다존 및 트라이아진온
MA40470A (fr) 2014-08-27 2016-03-03 Gilead Sciences Inc Composés et procédés d'inhibition des histones déméthylases
EP3204379B1 (en) 2014-10-10 2019-03-06 Genentech, Inc. Pyrrolidine amide compounds as histone demethylase inhibitors
US9637485B2 (en) 2014-11-03 2017-05-02 Hoffmann-La Roche Inc. 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection
CN104546886A (zh) * 2014-12-12 2015-04-29 安徽一灵药业有限公司 一种雷迪帕韦与索非布韦复方包衣片制剂及其制备方法

Also Published As

Publication number Publication date
BR112018073858A2 (pt) 2019-02-26
PL3463469T3 (pl) 2024-04-22
KR102202984B1 (ko) 2021-01-13
JP2020203947A (ja) 2020-12-24
CA3025633C (en) 2021-02-23
US11738013B2 (en) 2023-08-29
EP3463469C0 (en) 2023-12-13
JP2019519526A (ja) 2019-07-11
SG11201809893WA (en) 2018-12-28
ES2969239T3 (es) 2024-05-17
WO2017205078A1 (en) 2017-11-30
MA45088A (fr) 2019-04-10
CN118178652A (zh) 2024-06-14
CA3025633A1 (en) 2017-11-30
AU2017271990A1 (en) 2018-11-29
AU2017271990B2 (en) 2019-12-19
EP3463469A1 (en) 2019-04-10
EP3463469B1 (en) 2023-12-13
CN118178444A (zh) 2024-06-14
EA201892375A1 (ru) 2019-08-30
US20220117952A1 (en) 2022-04-21
JP6770098B2 (ja) 2020-10-14
CN109414508A (zh) 2019-03-01
KR20190010631A (ko) 2019-01-30

Similar Documents

Publication Publication Date Title
CO2020004202A2 (es) Compuestos químicos
IL282881A (en) Methods for treating hepatitis b infection
IL264575A (en) RNA materials for hepatitis b virus infection
EA201690452A1 (ru) Ингибиторы полимеразы hcv
EA201691726A1 (ru) Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
ZA202207262B (en) Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
EA201890731A1 (ru) Модуляторы корового белка гепатита b
MX2021012155A (es) Composiciones y metodos para el tratamiento de la anemia.
MX374244B (es) Compuesto de fosforamidato de nucleosido novedoso y su uso.
MX383929B (es) Derivados y métodos de tratamiento de las infecciones por hepatitis b.
MX2019003525A (es) Moduladores alostericos de proteina nucleo de hepatitis b.
MX2016009337A (es) Derivados de azepano y metodos para tratar infecciones por hepatitis b.
EA201270423A1 (ru) Ингибиторы протеазы hcv
EA201190013A1 (ru) Ингибиторы ns5a вгс
MX2016009828A (es) Nuevas dihidroquinolizinonas para el tratamiento y profilaxis de la infeccion por virus de la hepatitis b.
MX2018014377A (es) Metodos para tratar infecciones por virus de hepatitis b usando inhibidores de proteina no estructural 5a (ns5a), proteina no estructural 5b (ns5b) o proteina no estructural 3 (ns3).
BR112014030639A2 (pt) inibidores macrocíclicos de vírus flaviviridae
BR112014030630A2 (pt) inibidores macrocíclicos de vírus flaviviridae
EA201391152A1 (ru) Ингибиторы вируса гепатита с
MX2017000312A (es) Derivados de isoindolina para usarse en el tratamiento de una infeccion viral.
EP3380494A4 (en) METHOD FOR THE TREATMENT, PREVENTION AND DIAGNOSIS OF PORCINE EPIDEMIC DIARRHOE
EA201890818A1 (ru) Режим комбинированной терапии для лечения hcv
CL2016002361A1 (es) Compuestos derivados de azabenzofurano; composición farmacéutica, y su uso como inhibidores de la función de la proteína ns5b del hcv para el tratamiento de la hepatitis c.
HK40111347A (zh) 使用ns5a、ns5b或ns3抑制剂治疗乙型肝炎病毒感染的方法
HK40110857A (zh) 使用ns5a、ns5b或ns3抑制剂治疗乙型肝炎病毒感染的方法